Tirzepatide vs Semaglutide: What the Data Actually Shows

For years, the GLP-1 space had a frustrating gap: tirzepatide and semaglutide were both producing impressive results in separate trials, but no one had put them head-to-head in the same study. Indirect comparisons are useful but messy. Different patient populations, different protocols, different endpoints. Anyone who wanted a clean answer was left reading between the lines. Then SURMOUNT-5 published, and the gap closed.

The Trial That Settled It

SURMOUNT-5 was a randomized, double-blind, head-to-head trial that put tirzepatide (Zepbound/Mounjaro) directly against semaglutide (Wegovy/Ozempic) in adults with obesity or overweight plus at least one weight-related condition. Same trial, same timeframe, same endpoints. Over 72 weeks, participants on tirzepatide lost an average of 20.2% of their body weight. Those on semaglutide lost 13.7%.

Both arms used maximum tolerated doses: up to 15 mg weekly for tirzepatide and up to 2.4 mg weekly for semaglutide. This matters because you want the fairest possible fight. The trial wasn't comparing a high dose of one against a low dose of the other. Both drugs had room to perform at their best.

The result was clear. Tirzepatide produced roughly 47% more relative weight loss than semaglutide in the same controlled setting. That's not a marginal difference. For a field where shaving off an extra percentage point of body weight is considered clinically meaningful, a 6.5 percentage point gap is significant.

Why Tirzepatide Has the Edge

The short answer is that tirzepatide hits two receptors and semaglutide hits one. Semaglutide is a selective GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating. GLP-1 slows gastric emptying, suppresses appetite through signals to the hypothalamus, and improves insulin sensitivity. That's already a powerful combination. It's why semaglutide works as well as it does.

Tirzepatide adds GIP to that. GIP stands for glucose-dependent insulinotropic polypeptide, and it's a second incretin hormone. GIP amplifies insulin secretion after meals and appears to act synergistically with GLP-1 in adipose tissue, meaning the two pathways together produce more fat reduction than either one alone. Researchers are still working out the exact mechanisms, but the clinical signal is consistent across multiple studies: tirzepatide drives greater fat mass reduction, and specifically greater visceral fat reduction, compared to GLP-1 only approaches.

Visceral fat is the fat that wraps around your organs, the kind most tightly linked to metabolic disease, cardiovascular risk, and inflammation. The fact that tirzepatide appears to preferentially reduce it is one reason researchers are watching this drug closely for outcomes beyond just weight loss.

What 20.2% vs 13.7% Actually Means

Put those percentages into real terms. A 250-pound person on tirzepatide loses around 50 pounds on average over 72 weeks. That same person on semaglutide loses around 34 pounds. Both are genuinely meaningful results. Both are outcomes that prior-generation weight loss drugs couldn't touch. But 50 pounds and 34 pounds are different lives for a lot of people.

There's also the responder distribution to consider. Averages tell one story. The percentage of people who hit threshold responses tells another. In SURMOUNT-5, a larger proportion of tirzepatide participants crossed the 20% and 25% weight loss benchmarks compared to semaglutide. That means tirzepatide isn't just better on average. It's producing more people who achieve what you might call transformational outcomes.

72 weeks is also about 17 months. These are not quick results. Both drugs require gradual dose escalation to minimize side effects, and weight loss continues steadily over the course of the trial rather than dropping all at once in the first few months. Managing expectations matters here. These are long games.

Side Effects: Honest Assessment

Both drugs share the same basic side effect profile: nausea, vomiting, diarrhea, and constipation. These are GI effects driven by slowed gastric emptying, and they're most pronounced during dose escalation. For most people, they're manageable and taper off as the body adjusts. Eating smaller meals, avoiding high-fat foods, and titrating slowly all help.

In SURMOUNT-5, tirzepatide showed a slightly higher rate of GI side effects compared to semaglutide. That's the honest tradeoff: more weight loss, somewhat more nausea. But here's the part that gets buried in summary articles: discontinuation rates were comparable between the two groups. People were roughly equally likely to stop either drug due to side effects. The absolute difference in tolerability was not dramatic enough to drive meaningful differences in who stayed on treatment.

Other side effects worth knowing about for both drugs: injection site reactions (mild and uncommon), rare cases of pancreatitis, and the well-documented concern about muscle mass loss during rapid weight reduction. That last one isn't unique to these drugs, it comes with significant caloric restriction generally, but resistance training and adequate protein intake are routinely recommended for anyone on a GLP-1 class drug.

Who Should Choose Which

If maximum weight loss is the primary goal and there are no contraindications, the data currently points to tirzepatide. The efficacy advantage is real, it's been demonstrated in a head-to-head trial, and the mechanism behind it makes biological sense. That's not a weak case.

Semaglutide makes sense in a few specific situations. First, cardiovascular outcomes. The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events in people with pre-existing cardiovascular disease. The SUSTAIN-6 trial showed similar cardioprotective signals in diabetic populations. Tirzepatide's cardiovascular outcomes data is less mature. For someone with documented heart disease who needs proven CV risk reduction alongside weight loss, semaglutide has a stronger evidence base right now.

Second, access and cost. Insurance coverage, prior authorization requirements, and out-of-pocket costs vary significantly between these drugs depending on diagnosis, insurer, and geography. For some people, the practical answer is whichever drug their coverage will pay for. A drug that costs $1,400 a month out of pocket does nobody any good.

Third, individual tolerance. Some people respond unusually well to semaglutide and lose significant weight with fewer GI issues than they'd expect from tirzepatide's slightly higher side effect rate. Individual variation is real. If someone has tried semaglutide, responded well, and tolerates it without much difficulty, there's no urgent reason to switch just because the other drug has better average numbers.

The GLP-1 space is moving fast. Tirzepatide's long-term cardiovascular outcomes data will continue to mature, and drugs like retatrutide (a triple GIP/GLP-1/glucagon agonist) are already in late-stage trials showing even higher efficacy numbers. What looks like a settled comparison today may look different in two years. For now, though, if you're weighing these two drugs purely on what the current head-to-head evidence shows, tirzepatide is ahead.